Congratulations to the IPC Winners, Next Up RESI Boston, June 5-7

22 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Congratulations to all Innovator’s Pitch Challenge (IPC) finalists that participated in Digital RESI March last week. During the 3-day virtual conference, 30+ pitch companies were featured on a dedicated landing page that hosted their supplementary materials and participated in a live Q&A session with a panel of judges, who are active investors or industry experts in the space. They presented their unique and innovative technologies and products to the RESI attendees, and these technologies and products represent the future of life science arena. RESI attendees voted for their favorite pitch companies. Congratulations to the three IPC winners!

1st Place

Recognized as the 2022 Top Emerging Company at BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. BactPac is engineered to produce therapeutic payloads (mRNA, siRNA, proteins, and CRISPR/Cas) and safely deliver these payloads to targeted tissues (e.g., pancreas, lungs, heart and brain) that cannot be targeted by viral vectors and lipid nanoparticles (LNPs). BactPac can generate large and varied therapeutic moieties that have applications in a wide range of disease indications, including cancer, genetic, infectious, and chronic diseases. Using the BactPac platform, SiVEC is developing a first-in-class therapeutic pipeline targeting a range of therapeutic areas, including oncology, respiratory diseases, and rare genetic diseases. SiVEC has secured nearly $4M in NIH SBIR funding, has a strong patent portfolio, and has an early collaboration with a gene-editing company. We are seeking a $7M seed investment.

Check Out SiVEC Biotechnologies’ Dedicated Page

2nd Place

Reglagene is a therapeutics company dedicated to developing transformational therapies for brain diseases. Reglagene’s product RGN6024 demonstrated proof of concept, safely shrinking tumors in a therapy resistant animal model of brain cancer and beating todays standard of care head-to-head. RGN6024 is the subject of a 2023 patent filing, has a concise manufacturing process, and a risk-mitigating, diversified clinical development plan. We anticipate the start of human clinical trials in mid 2024. Reglagene’s second product in development leverages what we’ve learned from RGN6024 biology to target diseases driven by neuroinflammation, such as Parkinson’s Disease.

Check Out Reglagene’s Dedicated Page

3rd Place

Amplified Sciences is a clinical stage life science in-vitro diagnostics company with an ultra-sensitive molecular-sensing platform technology with composition of matter IP exclusively licensed from Purdue University focused on accurately detecting debilitating diseases sooner. Their lead assay for early detection of pancreatic cancer is supported with clinical published data and provides increased accuracy and earlier detection helping gastroenterologists stratify patients at risk for pancreatic cancer. Open $3M Series Seed Preferred, led by OCA Ventures and Elevate Ventures will fund opening of clinical lab, CLIA regulatory milestone, and support commercial launch in 2023 as well as scale additional assays on their ultrasensitive chemistry reagent platform.

Check Out Amplified Sciences’ Dedicated Page

The show never stops. If you missed the opportunity to pitch in March, applications are now open for RESI Boston, June 5-7. Apply to pitch in-person pitch on June 5. RESI Boston June is a hybrid format conference starting with a one day (June 5) in-person conference experience including partnering meeting, investor panels, IPC, workshops and Global Partnering Campaign and Roadshow Preparation classes at The Westin Copley Place in Boston, MA. Followed by two days (June 6-7) of a virtual partnering only event. Pitch applications are accepted on a rolling basis, so get yours in today!


Application deadline is Friday, April 21.

Want to be part of RESI Boston June? Register now to save $500 on super early bird rates by April 7. RESI also provides sponsorship and exhibition opportunities to help you increase your brand visibility at RESI Boston June or any future RESI conferences, contact us to learn more.


Digital RESI March – A Tailor Made Conference for Early-Stage Life Science Fundraising Startups

9 Mar

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Digital RESI March is merely days away, and It’s never too late for you to catch this terrific opportunity to meet with 250+ early-stage investors and licensing partners at a fraction of the overall cost of attending an in-person event. Fundraising is a numbers game and deals can take up to 9-18 months, so meeting with investors frequently can give you a competitive edge. Not only with partnering, in addition digital RESI March is designed with high-quality panels, pitch sessions, and Global Partnering Campaign and Roadshow Preparation Courses.

1:1 Partnering

LSN expects 250+ global investors at digital RESI March seeking new technology assets for their portfolios. LSN’s partnering events are international in scope and include companies across the silos of drugs, devices, diagnostics, digital health and R&D / life science tools. With the most powerful partnering platform RESI can match companies and partners based on stage of development and product fit.

Investor Panels & Workshops

Check out our impressive panels aimed at aiding early-stage CEOs as they navigate the fundraising landscape, while also providing insight for investors and strategic partners into the latest tech and industry developments.

Global Partnering Campaign and Roadshow Preparation Courses

Digital RESI March will feature a novel entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course, which will include six classes. This education focus will be for entrepreneurs who are starting to plan for their fundraising and licensing partner search and how LSN can help. An important theme for the education program will concern how to plan and execute a global roadshow efficiently, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape.

Innovator’s Pitch Challenge

34 life science innovators’ representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools will be delivering a short pitch followed by a Q&A session with a panel of investors and industry experts. At the meantime, the companies will have a dedicated landing page, including non-confidential materials of their company, that will be showcased to all RESI attendees as a way for participating companies to boost their exposure.

We look forward to seeing you at RESI next week! You can still register for the conference and engage in partnering meetings with attendees of interest, and join our robust program of investor panels, Entrepreneurial Education Courses, and pitch sessions.



Audience Access Pass – A Runway for Your Fundraising Journey

9 Mar

By Antoinette Lowre, Manager of Business Development, LSN

If you have checked out our lineup of content scheduled for next week but find yourself not ready to start your fundraising round and meet with investors and strategic partnering, consider the Audience Access registration option ($295).

The Audience Access pass allows you to take advantage of LSN’s Global Partnering Campaign and Roadshow Preparation courses, which is built into the agenda for Digital RESI March 14-16. You will also get access to watch all the live investor panels, and entrepreneur workshops, and attend the Innovator’s Pitch Challenge sessions to watch startup CEOs pitch.

The LSN Global Partnering Campaign and Roadshow Preparation course will include 6 classes, 2 per day over the 3 day conference. These courses are focused on where to start with planning and executing a global fundraising campaign and how LSN can help with our vast network of investors.


Another registration option is the RESI Bundle Package. A way to increase your fundraising opportunities and save $1000 to attend both Digital RESI March & RESI June 5-7 in Boston this summer. Check out the RESI Bundle Package options below!

One Ticket for 2 Conferences! 
More investor meetings and more savings with special RESI BUNDLES 
Digital RESI March 14-16
RESI June 5-7
The Westin Copley Place, Boston (June 5)
Virtual Partnering only (June 6-7)
Standard Bundle (March 14-16 & June 5-7) Digital Bundle (March 14-16 & June 6-7)
STARTUP $2,190 $3,190 $1,690 $2,690
SERVICE PROVIDER $2,990 $3,990 $2,290 $2,290
TECH HUB (Including Startup Who’ve Raised Less than $2MM USD ) $1,990 $2,390 $1,390 $2,390
Contact us to discuss further


Innovator’s Pitch Challenge Judges at Digital RESI March 

9 Mar

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The Innovator’s Pitch Challenge (IPC) has become one of the highlights of RESI, where entrepreneurs get a chance to pitch their companies to investors and industry experts, as well as RESI attendees in the audience. Digital RESI March will feature over 34 presenting companies across 9 sessions. Early-stage founders and CEOs will have 4-minutes to pitch and 8-9 minutes to engage in Q&A with the judge’s panel. LSN’s network of investors and strategic partners have actively participated in these sessions from the start and make both the IPC and RESI possible by their willingness to take part and give feedback. Below are the judges taking part in the IPC Q&A panels – thank you all for your participation!

Featured Digital RESI March IPC Judges

Ehi Akhirome
Norwest Venture Partners

Navid Alipour
Analytics Ventures

David Apfel
Johnson & Johnson Innovation

Priya Balachandran
Life Science Angels

Carl Barrett

Jay Batchu

Yael Benvenisti
Mediterranean Tower Ventures

Oded Biran
Individual Angel

Elsa Boukadoum

Bettina Ernst

David Fogel
Mass Medical Angels

Gita Gupta
NextStep Ventures

Tai Harada
Fast Track Initiative

Z Haroon
Julz Co

Ozan Isinak
Keiretsu Forum

Julia Kaufman
Boehringer Ingelheim Venture Fund

John Kim
Aphelion Capital

Merika Koday
Accelerator Life Science Partners

Will Krawczyk
Banner Venture Group

Cheryl Kuai
Sixty Degree Capital

Carla Lema Tome
Spark Therapeutics

Linda Li
Cleveland Clinic Ventures

Kevin Lin
Transcenta Holding

Fiona Mack

Alexander Martynov
Biovision Ventures

Milind Parate
Northwell Ventures

Laura Pedroza
High-Tech GrÜnderfonds

Stefan Pflanz
Boehringer Ingelheim Venture Fund

Armin Rump
Otsuka Pharmaceutical

Diana Saraceni
Panakes Partners

Goslik Schepers
Brandon Capital Partners

Shirin Schneeberger
Apollo Health Ventures

Randy Scott
HealthQuest Capital

Steve Seuntjens
Personal Health Solutions

Jill Sorensen
Medical Technology Enterprise Consortium (MTEC)

Karen Spilizewski
RiverVest Venture Partners

Santosh Vetticaden
NuFund Venture Group

Jingjing Wang
Lightstone Ventures

Aaron Welch
SymBiosis Capital Management


Hot Investor Mandate: Multi-Billion AUM Investment Firm Seeks to Invest in All Areas of Life Sciences & Healthcare Across the Globe

9 Mar

A leading healthcare investment firm, with multi-billion in assets under management invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. The firm seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. The firm’s team of over 100 professionals is based in USA, Asia, the Middle East, and other key global markets.

The firm invests in all modalities and indications across therapeutics, devices, diagnostics, and digital health, and have no specific preference for technology type.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Funding Arm of USA-Based Health System Invests in Digital Health Solutions With Strong Strategic Alignment

9 Mar

A newly established investment funding arm of a USA-based health system, one of the largest non-profit health systems in the USA is actively seeking new partnering opportunities. The firm’s objectives include fostering the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the firm’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: USA-Based VC Invests Up to $20M in Transformational Technologies in Therapeutics, Diagnostics, and Digital Health

9 Mar

A $1.2B AUM Seed through Series B venture firm based in the US typically invests between $500K to $20M. The firm focuses on two thematic areas – healthcare and enterprise SaaS. Within healthcare, the firm will invest in digital health, therapeutics, diagnostics and software-enabled medical devices. While somewhat flexible in stage, the firm prefers to have some POC for companies they invest in, such as some in vivo data, at least one hit for drug discovery, and a viable product/prototype for digital health and medical devices. The firm invests primarily in the US, but will invest in Canada as well.

Within healthcare, the firm invests in transformational technologies in all sectors. In therapeutics, the firm has an interest in cell & gene therapy and tissue engineering, but will invest in any modality if the technology is first-in-class. For small molecules or biologics, the firm does not invest in single assets. When investing in medical devices, the firm looks for those where software is a key component of the device. The firm invests in diagnostics and digital health as well, interested in technologies such as AI/ML technologies, drug discovery models, tech enabled services and data infrastructure, among others.

For later stage companies, the firm has no specific requirements. For seed stage companies, the firm is an active investor, and leads in most of their investments, taking a board seat. The firm is interested in companies with strong management teams, having strong expertise in the industry in which the startup is based.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: